Compare Heron Therapeutics Inc (HRTX) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Mercadolibre Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Mercadolibre Inc trades at $1,812.61 (market cap $92.90B). The key difference: Mercadolibre Inc is far larger — about 1015.7× Heron Therapeutics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | MELI | |
|---|---|---|
Market Cap | $91.46M | $92.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $2.51K |
52-Week Low | $0.39 | $1.55K |
Enterprise Value | $189.36M | $99.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
MercadoLibre (MELI) trades at $1,832.29, up 1.01% in the last session, while showing a bearish technical signal overall. The company reported strong revenue growth, with 2025 revenue reaching $28.89 billion, though recent quarterly EPS results have missed expectations. Operating cash flow improved significantly to $12.12 billion in 2025, and analyst sentiment remains strongly positive with a consensus price target of $2,230.
The outlook for MELI is supported by robust top-line expansion and strategic investments in logistics and fintech, but near-term margin pressure and recent earnings misses present risks. The stock offers growth potential in Latin American e-commerce and digital payments, balanced by competitive and execution challenges in a dynamic market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
